The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Diagnose, Manage and Treat Giant Cell Arteritis

Diagnose, Manage and Treat Giant Cell Arteritis

July 1, 2014 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Giant Cell Arteritis Challenging to Diagnose, Manage
  • Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Explore This Issue
July 2014
Also By This Author
  • Rheumatologist Lars Klareskog, MD, PhD, In the Spotlight
In half the field, the internal elastic lamina and media of a temporal artery are intact. In the other half, both have been destroyed and replaced by a granulomatous reaction and exudate that contains giant cells and epithelioid cells. The exudate extends into the intima, where there is extensive necrosis.
In half the field, the internal elastic lamina and media of a temporal artery are intact. In the other half, both have been destroyed and replaced by a granulomatous reaction and exudate that contains giant cells and epithelioid cells. The exudate extends into the intima, where there is extensive necrosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

SAN FRANCISCO—A granulomatous vasculitis of the aorta and its branches, giant cell arteritis (GCA) can cause blindness, stroke and aortic aneurysm. GCA is a “frightening” disease, said Cornelia M. Weyand, MD, PhD, professor of medicine, and chief, Division of Immunology and Rheumatology at Stanford University School of Medicine, Stanford, Calif., during her presentation at the California Rheumatology Alliance’s 10th Annual Medical and Scientific Meeting. Using case examples and humorous analogy, Dr. Weyand shared guidance for diagnosing GCA, lessons learned about the inflammatory cascade involved in the disease and implications for treating patients who develop it.

The Right Diagnosis

Presenting symptoms of GCA aortitis can include pulse deficits, fever, a highly elevated sedimentation rate, aneurysm or aortic dissection. GCA can co-occur with polymyalgia rheumatica. Age older than 50 years is a predominant risk factor, said Dr. Weyand, and can help clinicians differentiate patients with GCA from those with Takayasu’s arteritis (TA), which occurs almost exclusively in patients younger than 40 years. In addition, TA almost always affects the carotid arteries and the proximal parts of the subclavian arteries, and frequently is seen in abdominal branches of the aorta; GCA has a preference for the distal subclavian and axillary arteries.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Radiology colleagues can be powerful allies during the diagnostic process. “CT angiography,” Dr. Weyand asserted, “gives us fast and very reliable data on whether patients have large vessel involvement. You need to work with your radiologist to be sure you look not only at the core of the aorta and the large vessels, but also into the periphery.” PET scans, she added, “are not as sensitive as we hoped they would be, particularly in patients that are on treatment.” There may be advances with new combined PET/MRI technology (Note: In January, Stanford installed the world’s first fully integrated PET/MRI scanner), but that has yet to be demonstrated.

Compared with men, women are at greater risk for pain undertreatment. “Maybe it’s because women exprThere is no evidence right now that if you were to stop the disease entirely that the prognosis of our patients would improve.

What Goes Wrong?

Dr. Weyand shared lessons learned from her research into the mechanisms of inflammatory blood vessel disease conducted with colleagues at both Stanford University and the Mayo Clinic in Rochester, Minn. In GCA, vascular inflammation results from a domino effect of activated cytokines, producing a sort of “cytokine soup.” Macrophages cohere to form granulomas, often within the medial layer of the aorta. The site of entrance for the inflammatory cells is the adventitia in the outer lining of the aorta, she pointed out. Analysis of cell lesions has demonstrated a complex makeup of two different T-cell populations in addition to three different dendritic cell populations. As opposed to atherosclerosis, in which lesions form in the interior of the blood vessel, in GCA the disease process starts “at the back door.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Career Development, Conditions, Education & Training, Professional Topics, Vasculitis Tagged With: Cornelia M. Weyand, CRA, GCA, Giant Cell Arteritis, imaging, Steroids, Takayasu’s Arteritis, VasculitisIssue: July 2014

You Might Also Like:
  • Giant Cell Arteritis Challenging to Diagnose, Manage
  • Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Varicella Zoster Virus May Cause Giant Cell Arteritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)